LTRN | tickerfilter.com

Fundamental analysis

21%

Profitability 0%

Dept financing 4%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-13.71%

1 Month

-26.07%

3 Months

-33.68%

6 Months

-26.91%

1 Year

-66.75%

2 Year

-47.02%

Key data

Stock price

$2.58

P/E Ratio

0.00

DAY RANGE

$2.55 - $2.99

EPS

-$1.93

52 WEEK RANGE

$2.55 - $7.62

52 WEEK CHANGE

-$66.67

MARKET CAP

34.403 M

YIELD

N/A

SHARES OUTSTANDING

10.765 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

2.73

PUBLIC FLOAT

AVERAGE 10 VOLUME

$46,991

AVERAGE 30 VOLUME

$32,312

Company detail

CEO: Panna L. Sharma
Region: US
Website: lanternpharma.com
Employees: 20
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

LTRN - Lantern Pharma Inc.